Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · IEX Real-Time Price · USD
0.932
-0.022 (-2.31%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Lineage Cell Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for LCTX stock have an average target of 6.50, with a low estimate of 6.00 and a high estimate of 7.00. The average target predicts an increase of 597.35% from the current stock price of 0.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 6, 2024.
Analyst Ratings
The average analyst rating for LCTX stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +650.99% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +650.99% | Mar 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +650.99% | Feb 13, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $6 | Buy | Reiterates | $6 | +543.71% | Feb 5, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +650.99% | Aug 11, 2023 |
Financial Forecast
Revenue This Year
12.48M
from 8.95M
Increased by 39.47%
Revenue Next Year
8.89M
from 12.48M
Decreased by -28.71%
EPS This Year
-0.12
from -0.12
EPS Next Year
-0.18
from -0.12
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 37.6M | 26.6M | 62.8M | 194.0M | 367.2M |
| Avg | 12.5M | 8.9M | 59.0M | 69.4M | 155.1M |
| Low | 1.4M | 1.8M | 54.8M | 3.3M | 3.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 320.8% | 112.9% | 606.0% | 228.7% | 429.1% |
| Avg | 39.5% | -28.7% | 563.4% | 17.6% | 123.6% |
| Low | -84.7% | -85.6% | 515.9% | -94.4% | -95.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.02 | -0.08 | -0.19 | -0.15 | -0.14 |
| Avg | -0.12 | -0.18 | -0.24 | -0.14 | -0.13 |
| Low | -0.20 | -0.25 | -0.28 | -0.14 | -0.13 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.